OHTUVAYRE Earns FDA Patent Review Period Boost
Published Date: 8/26/2025
Notice
Summary
The FDA has officially set the review period for OHTUVAYRE, a human drug product, so its patent can be extended. This helps the drug maker get extra time to protect their invention after the long approval process. If you’re involved in drug patents or development, this means important deadlines and opportunities to keep an invention exclusive.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Sets Patent-Extension Period for OHTUVAYRE
The FDA determined the regulatory review period for the human drug OHTUVAYRE so the drug maker may submit applications to the U.S. Patent and Trademark Office to extend patents that claim the drug. This official determination creates the administrative basis for the company to seek extra time of patent exclusivity after the drug approval process.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in